Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Transil Membrane Affinity and Transil Human Serum Albumin Binding Assay Kits and Select Biosciences Reports

Premium

Molecular Devices said last week that it has introduced Transil Membrane Affinity and Transil Human Serum Albumin Binding assay kits — two new reagent products for ADME assay screening.

According to MDCC, the Transil Membrane Affinity assay uses beads that are coated with a lipid bilayer that mimic interactions between compounds and cell membranes. The Transil HAS Binding assay contains beads that have been coated with human serum albumin and pre-dispensed into a microplate format, which increases throughput on the company’s SpectraMax microplate readers. Both kits are available in 96- or 384-well microplate formats, MDCC said.


Select Biosciences has three new reports available, the UK-based market research firm said this week. GPCR Assay Trends examines “the relative importance of GPCR primary screening and selectivity profiling both in house and outsourced, the preferences of respondents for assay detection technologies, and suppliers/products and fee-for-service providers;” Ion Channel Trends covers “the importance of ion channel targets, ion channel selectivity profiling, outsourcing, and the potential impact of high throughput electrophysiology on these activities;” and Transporter Assay Trends focuses on “the number of transporter targets screened, data points per screen, and costs associated with screening” to assist companies trying to bring to the market new technologies for the assay of transporters.

 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more